Cholangiopancreatography, Endoscopic RetrogradeNCT06689033
High Flow Nasal Oxygen Versus Standard Nasal Oxygen in Endoscopic Retrograde Cholangiopancreatography Under Sedation
An observational study of Cholangiopancreatography, Endoscopic Retrograde and Hypoxia, run by Ankara City Hospital Bilkent at 1 site in Turkey (Türkiye).
Trial summary
The administration of supplemental oxygen using a standard nasal cannula is the current standard of care for patients undergoing sedation for gastrointestinal endoscopic procedures. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cholangiopancreatography, Endoscopic Retrograde, Hypoxia, Sedation
- How many people
- 187 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Apr 2023to 30 Nov 2023
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients scheduled for ERCP procedure under sedation in Ankara City Hospital's Gastrointestinal Endoscopy Colonoscopy Unit are included.
Who may be able to join
- Voluntary patients over 18 years of age
- ASA (American Society of Anaesthesiologists) I-IV risk scores
Who cannot join
- Patients with altered mental status, dementia, cognitive disorders
- Intubation
- Tracheostomies
- Need for oxygen therapy due to preexisting disease
- Pregnancy
- Recent history of nasal bleeding
- Allergy to propofol
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Ankara Bilkent City Hospital, Department of Anesthesiology
Ankara, 06800
About this study
Official title: Comparison of High Flow Nasal Oxygen and Standard Nasal Oxygen in Preventing Hypoxia in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography Under Sedation
The administration of supplemental oxygen using a standard nasal cannula is the current standard of care for patients undergoing sedation for gastrointestinal endoscopic procedures. Endoscopic Retrograde Cholangio Pancreatography can be particularly challenging for anesthesiologists due to the increased difficulty in airway access when performed in the prone position. High-flow nasal oxygen is a non-invasive oxygen therapy system that can provide heated and humidified air containing oxygen at a high flow rate.This study aims to compare the effectiveness of High Flow Nasal Oxygen versus standard nasal oxygen in preventing hypoxemia in patients undergoing deep sedation during ERCP procedures.
Read the detailed description
Ankara City Hospital's Gastrointestinal Endoscopy Colonoscopy Unit's patient count determined using G-power statistical software ensured that a sample size of at least 185 patients was adequate at a 95% confidence level with 80% power and an effect size of 0.5. Analyses were performed using the Power and Sample Size statistical program version 3.1.2 (Vanderbilt University, 2015).
187 patients scheduled for ERCP procedure under sedation during an 8-month period were included in the study. The study was planned as a randomized observational and prospective study. Patients were randomly allocated to either the nasal oxygen (NO) or High Flow Nasal Oxygen (HFNO) group in a 1:1 ratio using a computer-generated random code generator. It was not a blind study, as the oxygen delivery systems did not look the same. Endoscopists, anesthesiologists, and patients were not blinded. ERCP procedures were completed by one of two expert endoscopists and sedation was performed by one of two anesthesiologists trained in endoscopic sedation. The study and possible risks were explained to all patients participating in the study, and written informed consent was obtained from the patients. The patient's age, current chronic diseases, and duration of the procedure were recorded. Before the procedure, the frailty level of the patients was evaluated with the Modified Frailty Index-11 (mFI-11) and recorded. The mFI-11 is an 11-item index that assesses comorbidities to stratify patient risk. The simplified frailty index is calculated as the number of present comorbidities divided by the total number of 11 items used in the mFI-11 assessment, which includes diabetes mellitus, not independent functional status, chronic obstructive pulmonary disease, congestive heart failure, myocardial infarction, percutaneous coronary intervention or cardiac surgery, angina, hypertension medication, peripheral vascular disease, impaired sensorium, transient ischemic attack, and cerebrovascular accident. The resulting score ranges from 0 to 1. Patients were positioned prone and pulse oximetry, non-invasive blood pressure monitoring, electrocardiography, and Bispectral Index monitoring were performed, and baseline values were recorded in all cases. The NO group was preoxygenated with 100% oxygen for 3 min with an oxygen flow rate of 8 L.min-1 via a nasal cannula before induction and received 100% oxygen with a flow rate of 5 L.min-1 throughout the procedure. The HFNO group was preoxygenated with 100% oxygen with a flow rate of 40 L.min-1 for 3 min via an HFNO system (Inspired 02FLO High Flow Heated Respiratory Humidifier, VUN-001, Vincent Medical Manufacturing Co., Hong Kong) before induction and received 50% oxygen with a flow rate of 50 L.min-1. In case of a decrease in saturation (SpO2<90), the flow was increased to 60 L.min-1, and if it did not resolve, FiO2 was increased to 100%. All patients were premedicated with iv midazolam and sedation was performed with iv 1 µg.kg-1 fentanyl and iv bolus dose of 0.5-1 mg.kg-1 %1 propofol followed by an iv infusion of propofol 3-4 mg.kg-1.hr-1 targeting a BIS value of 60-80. In case of apnea or desaturation, maneuvers such as patient stimulation, chin lifting, or increasing oxygen flow were performed and recorded. The lowest SpO2 values obtained for both groups were noted.
The data were analyzed using IBM SPSS Statistics ver. 25 (IBM Corporation, Armonk, NY, USA). The distribution of continuous numerical variables was tested for normality using the Kolmogorov-Smirnov test, and the homogeneity of variances was assessed with Levene's test. Descriptive statistics were expressed as mean ± standard deviation or range (minimum - maximum) for continuous variables, and as case number and percentage (%) for categorical variables. The significance of differences between the NO and HFNO groups for continuous variables that met the assumptions of parametric test statistics was evaluated using Student's t-test, whereas differences for those that did not meet these assumptions were assessed using the Mann-Whitney U test. The significance of changes over time in systolic, diastolic, and mean blood pressure, heart rate, oxygen saturation (SpO2), and BIS levels was examined using repeated measures analysis of variance with Wilks' Lambda test. Where Wilks' Lambda test results were found significant, the specific times causing the differences were identified using the Bonferroni-adjusted multiple comparison test. Comparisons between the NO and HFNO groups were made by calculating the changes in SpO2 and BIS from baseline at subsequent time points. Unless otherwise stated, Pearson's χ2 test was used for the analysis of categorical data. For 2x2 contingency tables where at least 25% of the expected frequencies were below 5, Fisher's exact test was used, and where expected frequencies were between 5 and 25, the continuity-adjusted χ2 test was employed. In RxC tables (where at least one of the categorical variables in the row or column had more than two outcomes), if at least 25% of the cells had expected frequencies below 5, the Fisher-Freeman-Halton test was applied. Unless stated otherwise, results were considered statistically significant at p<0.05. However, to control for Type I error in all multiple comparisons, Bonferroni correction was applied.
- Keywords
- HFNO, sedation, prone position, Cholangiopancreatography, Endoscopic Retrograde
- Medical subject headings
- Hypoxia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Group 1: Patients sedated for ERCP, receiving nasal oxygen | Nasal Oxygen, preoxygenation with 100% oxygen for 3 min with an oxygen flow rate of 8 L.min-1 via a nasal cannula before induction and 100% oxygen with a flow rate of 5 L.min-1 throughout the procedure. | |
| Group 2: Patients sedated for ERCP receiving high flow nasal oxygen | High flow nasal oxygen, preoxygenation with 100% oxygen with a flow rate of 40 L.min-1 for 3 min before induction and received 50% oxygen with a flow rate of 50 L.min-1. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Oxygen saturation SpO2 levels of the cases in %
Each patient was monitored with an oxygen saturation probe and SpO2 levels of the cases were recorded before induction of sedation and every 5 minutes, throughout the procedure. Hypoxemia was detected.
Measured: Oxygen saturation levels were recorded before induction and every 5 minutes throughout the procedure that lasted around 30 minutes.
Secondary outcomes (1)
Number of interventions over procedure time (number)
In case of apnea or desaturation, airway interventions were performed and recorded throughout the procedure
Measured: Number of maneuvers performed throughout the procedure, that lasted around 30 minutes were recorded.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Nov 2024
- Study start1 Apr 2023
- Primary completion30 Nov 2023
- Study completion30 Nov 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for Cholangiopancreatography, Endoscopic RetrogradeStudies of the same condition, open and under way.
- More trials run by Ankara City Hospital BilkentThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 187 participants (actual)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Ankara City Hospital Bilkent
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Ezgi Erkilic, Associate Professor, Principal investigator, Ankara Bilkent City Hospital, Department of Anesthesiology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06689033
- Sponsor's protocol ID
- E2-23-4070
- Status last verified
- Nov 2024
- First submitted
- 28 Oct 2024
- Last updated
- 14 Nov 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data will be shared after publication of the study. Study protocol, statistical analysis, study report will be shared if required by a researcher.
Publications
Carron M, Tamburini E, Safaee Fakhr B, De Cassai A, Linassi F, Navalesi P. High-flow nasal oxygenation during gastrointestinal endoscopy. Systematic review and meta-analysis. BJA Open. 2022 Oct 18;4:100098. doi: 10.1016/j.bjao.2022.100098. eCollection 2022 Dec.
PubMed 37588780Sawase H, Ozawa E, Yano H, Ichinomiya T, Yano R, Miyaaki H, Komatsu N, Ayuse T, Kurata S, Sato S, Pinkham MI, Tatkov S, Ashizawa K, Nagata K, Nakao K. Respiratory support with nasal high flow without supplemental oxygen in patients undergoing endoscopic retrograde cholangiopancreatography under moderate sedation: a prospective, randomized, single-center clinical trial. BMC Anesthesiol. 2023 May 8;23(1):156. doi: 10.1186/s12871-023-02125-w.
PubMed 37158818Zhang YX, He XX, Chen YP, Yang S. The effectiveness of high-flow nasal cannula during sedated digestive endoscopy: a systematic review and meta-analysis. Eur J Med Res. 2022 Feb 24;27(1):30. doi: 10.1186/s40001-022-00661-8.
PubMed 35209948Douglas N, Ng I, Nazeem F, Lee K, Mezzavia P, Krieser R, Steinfort D, Irving L, Segal R. A randomised controlled trial comparing high-flow nasal oxygen with standard management for conscious sedation during bronchoscopy. Anaesthesia. 2018 Feb;73(2):169-176. doi: 10.1111/anae.14156. Epub 2017 Nov 24.
PubMed 29171661Corral-Blanco M, Sayas-Catalan J, Hernandez-Voth A, Rey-Terron L, Villena-Garrido V. High-Flow Nasal Cannula Therapy as an Adjuvant Therapy for Respiratory Support during Endoscopic Techniques: A Narrative Review. J Clin Med. 2023 Dec 22;13(1):81. doi: 10.3390/jcm13010081.
PubMed 38202089Cha B, Lee MJ, Park JS, Jeong S, Lee DH, Park TG. Clinical efficacy of high-flow nasal oxygen in patients undergoing ERCP under sedation. Sci Rep. 2021 Jan 11;11(1):350. doi: 10.1038/s41598-020-79798-7.
PubMed 33432035Lee MJ, Cha B, Park JS, Kim JS, Cho SY, Han JH, Park MH, Yang C, Jeong S. Impact of High-Flow Nasal Cannula Oxygenation on the Prevention of Hypoxia During Endoscopic Retrograde Cholangiopancreatography in Elderly Patients: A Randomized Clinical Trial. Dig Dis Sci. 2022 Aug;67(8):4154-4160. doi: 10.1007/s10620-021-07272-z. Epub 2021 Nov 2.
PubMed 34727281Kim SH, Bang S, Lee KY, Park SW, Park JY, Lee HS, Oh H, Oh YJ. Comparison of high flow nasal oxygen and conventional nasal cannula during gastrointestinal endoscopic sedation in the prone position: a randomized trial. Can J Anaesth. 2021 Apr;68(4):460-466. doi: 10.1007/s12630-020-01883-2. Epub 2021 Jan 6.
PubMed 33403549
Study at a glance
From the registry record, last updated by the sponsor on 14 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of High Flow Nasal Oxygen and Standard Nasal Oxygen in Preventing Hypoxia in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography Under Sedation
- ClinicalTrials.gov ID
- NCT06689033
- Acronym / sponsor ID
- E2-23-4070
- Keywords
- HFNO, sedation, prone position, Cholangiopancreatography, Endoscopic Retrograde
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 187 participants (actual)
- Lead sponsor
- Ankara City Hospital BilkentUniversity, hospital or other
- Study start
- 1 Apr 2023 (actual)
- Primary completion
- 30 Nov 2023 (actual)
- Study completion
- 30 Nov 2023 (actual)
- First posted
- 14 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The administration of supplemental oxygen using a standard nasal cannula is the current standard of care for patients undergoing sedation for gastrointestinal endoscopic procedures. Endoscopic Retrograde Cholangio Pancreatography can be particularly challenging for anesthesiologists due to the increased difficulty in airway access when performed in the prone position. High-flow nasal oxygen is a non-invasive oxygen therapy system that can provide heated and humidified air containing oxygen at a high flow rate.This study aims to compare the effectiveness of High Flow Nasal Oxygen versus standard nasal oxygen in preventing hypoxemia in patients undergoing deep sedation during ERCP procedures.
Detailed description
Ankara City Hospital's Gastrointestinal Endoscopy Colonoscopy Unit's patient count determined using G-power statistical software ensured that a sample size of at least 185 patients was adequate at a 95% confidence level with 80% power and an effect size of 0.5. Analyses were performed using the Power and Sample Size statistical program version 3.1.2 (Vanderbilt University, 2015).
187 patients scheduled for ERCP procedure under sedation during an 8-month period were included in the study. The study was planned as a randomized observational and prospective study. Patients were randomly allocated to either the nasal oxygen (NO) or High Flow Nasal Oxygen (HFNO) group in a 1:1 ratio using a computer-generated random code generator. It was not a blind study, as the oxygen delivery systems did not look the same. Endoscopists, anesthesiologists, and patients were not blinded. ERCP procedures were completed by one of two expert endoscopists and sedation was performed by one of two anesthesiologists trained in endoscopic sedation. The study and possible risks were explained to all patients participating in the study, and written informed consent was obtained from the patients. The patient's age, current chronic diseases, and duration of the procedure were recorded. Before the procedure, the frailty level of the patients was evaluated with the Modified Frailty Index-11 (mFI-11) and recorded. The mFI-11 is an 11-item index that assesses comorbidities to stratify patient risk. The simplified frailty index is calculated as the number of present comorbidities divided by the total number of 11 items used in the mFI-11 assessment, which includes diabetes mellitus, not independent functional status, chronic obstructive pulmonary disease, congestive heart failure, myocardial infarction, percutaneous coronary intervention or cardiac surgery, angina, hypertension medication, peripheral vascular disease, impaired sensorium, transient ischemic attack, and cerebrovascular accident. The resulting score ranges from 0 to 1. Patients were positioned prone and pulse oximetry, non-invasive blood pressure monitoring, electrocardiography, and Bispectral Index monitoring were performed, and baseline values were recorded in all cases. The NO group was preoxygenated with 100% oxygen for 3 min with an oxygen flow rate of 8 L.min-1 via a nasal cannula before induction and received 100% oxygen with a flow rate of 5 L.min-1 throughout the procedure. The HFNO group was preoxygenated with 100% oxygen with a flow rate of 40 L.min-1 for 3 min via an HFNO system (Inspired 02FLO High Flow Heated Respiratory Humidifier, VUN-001, Vincent Medical Manufacturing Co., Hong Kong) before induction and received 50% oxygen with a flow rate of 50 L.min-1. In case of a decrease in saturation (SpO2<90), the flow was increased to 60 L.min-1, and if it did not resolve, FiO2 was increased to 100%. All patients were premedicated with iv midazolam and sedation was performed with iv 1 µg.kg-1 fentanyl and iv bolus dose of 0.5-1 mg.kg-1 %1 propofol followed by an iv infusion of propofol 3-4 mg.kg-1.hr-1 targeting a BIS value of 60-80. In case of apnea or desaturation, maneuvers such as patient stimulation, chin lifting, or increasing oxygen flow were performed and recorded. The lowest SpO2 values obtained for both groups were noted.
The data were analyzed using IBM SPSS Statistics ver. 25 (IBM Corporation, Armonk, NY, USA). The distribution of continuous numerical variables was tested for normality using the Kolmogorov-Smirnov test, and the homogeneity of variances was assessed with Levene's test. Descriptive statistics were expressed as mean ± standard deviation or range (minimum - maximum) for continuous variables, and as case number and percentage (%) for categorical variables. The significance of differences between the NO and HFNO groups for continuous variables that met the assumptions of parametric test statistics was evaluated using Student's t-test, whereas differences for those that did not meet these assumptions were assessed using the Mann-Whitney U test. The significance of changes over time in systolic, diastolic, and mean blood pressure, heart rate, oxygen saturation (SpO2), and BIS levels was examined using repeated measures analysis of variance with Wilks' Lambda test. Where Wilks' Lambda test results were found significant, the specific times causing the differences were identified using the Bonferroni-adjusted multiple comparison test. Comparisons between the NO and HFNO groups were made by calculating the changes in SpO2 and BIS from baseline at subsequent time points. Unless otherwise stated, Pearson's χ2 test was used for the analysis of categorical data. For 2x2 contingency tables where at least 25% of the expected frequencies were below 5, Fisher's exact test was used, and where expected frequencies were between 5 and 25, the continuity-adjusted χ2 test was employed. In RxC tables (where at least one of the categorical variables in the row or column had more than two outcomes), if at least 25% of the cells had expected frequencies below 5, the Fisher-Freeman-Halton test was applied. Unless stated otherwise, results were considered statistically significant at p<0.05. However, to control for Type I error in all multiple comparisons, Bonferroni correction was applied.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Target follow-up
- 1 Day
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group 1: Patients sedated for ERCP, receiving nasal oxygen | – | –Nasal Oxygen, preoxygenation with 100% oxygen for 3 min with an oxygen flow rate of 8 L.min-1 via a nasal cannula before induction and 100% oxygen with a flow rate of 5 L.min-1 throughout the procedure. |
| Group 2: Patients sedated for ERCP receiving high flow nasal oxygen | – | –High flow nasal oxygen, preoxygenation with 100% oxygen with a flow rate of 40 L.min-1 for 3 min before induction and received 50% oxygen with a flow rate of 50 L.min-1. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients scheduled for ERCP procedure under sedation in Ankara City Hospital's Gastrointestinal Endoscopy Colonoscopy Unit are included.
Key inclusion criteria (2 listed)
- Voluntary patients over 18 years of age
- ASA (American Society of Anaesthesiologists) I-IV risk scores
Key exclusion criteria (7 listed)
- Patients with altered mental status, dementia, cognitive disorders
- Intubation
- Tracheostomies
- Need for oxygen therapy due to preexisting disease
- Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Oxygen saturation SpO2 levels of the cases in %
Time frame: Oxygen saturation levels were recorded before induction and every 5 minutes throughout the procedure that lasted around 30 minutes.
Each patient was monitored with an oxygen saturation probe and SpO2 levels of the cases were recorded before induction of sedation and every 5 minutes, throughout the procedure. Hypoxemia was detected.
1 secondary outcome
Number of interventions over procedure time (number)
Time frame: Number of maneuvers performed throughout the procedure, that lasted around 30 minutes were recorded.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Nov 2024.
- Background: PubMed 37588780Carron M, Tamburini E, Safaee Fakhr B, De Cassai A, Linassi F, Navalesi P. High-flow nasal oxygenation during gastrointestinal endoscopy. Systematic review and meta-analysis. BJA Open. 2022 Oct 18;4:100098. doi: 10.1016/j.bjao.2022.100098. eCollection 2022 Dec.
- Background: PubMed 37158818Sawase H, Ozawa E, Yano H, Ichinomiya T, Yano R, Miyaaki H, Komatsu N, Ayuse T, Kurata S, Sato S, Pinkham MI, Tatkov S, Ashizawa K, Nagata K, Nakao K. Respiratory support with nasal high flow without supplemental oxygen in patients undergoing endoscopic retrograde cholangiopancreatography under moderate sedation: a prospective, randomized, single-center clinical trial. BMC Anesthesiol. 2023 May 8;23(1):156. doi: 10.1186/s12871-023-02125-w.
- Background: PubMed 35209948Zhang YX, He XX, Chen YP, Yang S. The effectiveness of high-flow nasal cannula during sedated digestive endoscopy: a systematic review and meta-analysis. Eur J Med Res. 2022 Feb 24;27(1):30. doi: 10.1186/s40001-022-00661-8.
- Background: PubMed 29171661Douglas N, Ng I, Nazeem F, Lee K, Mezzavia P, Krieser R, Steinfort D, Irving L, Segal R. A randomised controlled trial comparing high-flow nasal oxygen with standard management for conscious sedation during bronchoscopy. Anaesthesia. 2018 Feb;73(2):169-176. doi: 10.1111/anae.14156. Epub 2017 Nov 24.
- Background: PubMed 38202089Corral-Blanco M, Sayas-Catalan J, Hernandez-Voth A, Rey-Terron L, Villena-Garrido V. High-Flow Nasal Cannula Therapy as an Adjuvant Therapy for Respiratory Support during Endoscopic Techniques: A Narrative Review. J Clin Med. 2023 Dec 22;13(1):81. doi: 10.3390/jcm13010081.
- Background: PubMed 33432035Cha B, Lee MJ, Park JS, Jeong S, Lee DH, Park TG. Clinical efficacy of high-flow nasal oxygen in patients undergoing ERCP under sedation. Sci Rep. 2021 Jan 11;11(1):350. doi: 10.1038/s41598-020-79798-7.
- Background: PubMed 34727281Lee MJ, Cha B, Park JS, Kim JS, Cho SY, Han JH, Park MH, Yang C, Jeong S. Impact of High-Flow Nasal Cannula Oxygenation on the Prevention of Hypoxia During Endoscopic Retrograde Cholangiopancreatography in Elderly Patients: A Randomized Clinical Trial. Dig Dis Sci. 2022 Aug;67(8):4154-4160. doi: 10.1007/s10620-021-07272-z. Epub 2021 Nov 2.
- Background: PubMed 33403549Kim SH, Bang S, Lee KY, Park SW, Park JY, Lee HS, Oh H, Oh YJ. Comparison of high flow nasal oxygen and conventional nasal cannula during gastrointestinal endoscopic sedation in the prone position: a randomized trial. Can J Anaesth. 2021 Apr;68(4):460-466. doi: 10.1007/s12630-020-01883-2. Epub 2021 Jan 6.
- Individual participant dataSharing planned: Yes. Data will be shared after publication of the study. Study protocol, statistical analysis, study report will be shared if required by a researcher.
Related trials for Cholangiopancreatography, Endoscopic Retrograde
Not yet recruiting
XRAIconnect Image Guidance Software for ERCP Procedures
Patients Scheduled for Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedure
Recruiting
HFNC Versus Microstream Advance Nasal Cannula for Oxygenation During ERCP
Endoscopic Retrograde Cholangiopancreatography, Hypoxemia
Not yet recruiting
TEAS for Sedation During ERCP: A Multicenter Trial With Mechanistic Substudy
Endoscopic Retrograde Cholangiopancreatography, Conscious Sedation Adverse Event
Not yet recruiting
Opioid-Free Versus Opioid-Based Sedation for Endoscopic Procedures
Sedation, Endoscopy
Not yet recruiting
A 2×2 Factorial Randomized Controlled Trial for ERCP
Biliary and Pancreatic Diseases, Endoscopic Retrograde Cholangiopancreatography (ERCP)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ezgi Erkilic, Associate Professor principal investigator
Ankara Bilkent City Hospital, Department of Anesthesiology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cholangiopancreatography, Endoscopic Retrograde and Hypoxia, run by Ankara City Hospital Bilkent at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Oxygen saturation SpO2 levels of the cases in % (time frame: Oxygen saturation levels were recorded before induction and every 5 minutes throughout the procedure that lasted around 30 minutes.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06689033, which also lists 8 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Nov 2024; AzTrials last refreshed its copy on 6 Nov 2026.